(Q36584367)

15 August 2017

1 reference

title

Chapter 16: HPV vaccines in immunocompromised women and men. (English)

1 reference

15 August 2017

1 reference

3

Howard D Strickler

1 reference

15 August 2017

2

Maura L Gillison

1 reference

15 August 2017

Joel M Palefsky

1

1 reference

PubMed ID

16950001

15 August 2017

language of work or name

English

0 references

publication date

23 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

24 Suppl 3

1 reference

15 August 2017

S3/140-6

1 reference

A controlled trial of a human papillomavirus type 16 vaccine

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Cancer risk following organ transplantation: a nationwide cohort study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Sexually transmitted infection as a cause of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

HIV-Associated Anal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Prevalence and risk factors for anal squamous intraepithelial lesions in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

The global health burden of infection-associated cancers in the year 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Oral cancer in Southern India: the influence of body size, diet, infections and sexual practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Vaccinations for adult solid organ transplant recipient: current recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Safety and immunogenicity of influenza vaccination in individuals infected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.120

10.1016/J.VACCINE.2006.05.120

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16950001